Upadacitinib
- Generic Name
- Upadacitinib
- Brand Names
- Rinvoq
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19F3N6O
- CAS Number
- 1310726-60-3
- Unique Ingredient Identifier
- 4RA0KN46E0
- Background
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, auto...
- Indication
Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as TNF blockers. In Europe, upadacitinib may be used as monotherapy or in combination with met...
- Associated Conditions
- Ankylosing Spondylitis (AS), Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Severe Atopic Dermatitis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis, Severe, active Crohn´s Disease
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.